Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES. - Szarek M; Reijnders E; Steg PG; Jukema JW; Schwertfeger M; Bhatt DL; Bittner VA; Diaz R; Fazio S; Garon G; Goodman SG; Harrington RA; et al. (European journal of preventive cardiology, 2024)